Compare General Motors Company (GM) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
General Motors Company vs Regeneron Pharmaceuticals Inc — how do they compare? General Motors Company trades at $89.6 (market cap $76.85B), while Regeneron Pharmaceuticals Inc trades at $799 (market cap $83.19B). The key difference: General Motors Company and Regeneron Pharmaceuticals Inc are close in size by market cap, and General Motors Company pays the higher dividend (0.82%). Which is the better fit depends on your goals.
| GM | REGN | |
|---|---|---|
Market Cap | $76.85B | $83.19B |
Sector | Consumer Cyclical | Health |
52-Week High | $90.30 | $812.27 |
52-Week Low | $54.01 | $545.94 |
Enterprise Value | $179.83B | $77.90B |
Dividend Yield | 0.82% | 0.47% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
General Motors (GM) trades at $87.58, up 0.74% today, showing strong technical momentum with a bullish moving average signal and support at $87. The company has delivered three consecutive quarterly earnings beats, with Q2 2026 EPS of $3.57 beating expectations of $3.19. Recent developments include the renewal of GM's China joint venture with SAIC for 20 years and expansion of EV charging infrastructure with Pilot and EVgo.
GM presents a compelling investment case with analyst consensus price target of $108.82 (24% upside), strong institutional support (65% buy ratings), and improving cash flow trends. However, risks include declining profit margins (1.05% net margin in 2025), rising debt levels, and competitive pressures in the EV transition. The stock offers value with attractive valuation multiples (P/S 0.44, P/B 1.24) but requires monitoring of margin sustainability.
Regeneron Pharmaceuticals (REGN) trades at $784.36, up 1.59% today, with a bullish technical signal from moving averages but overbought RSI readings. The company shows strong profitability with a net income margin of 27.86% and has beaten EPS estimates in recent quarters. However, multiple class-action lawsuits filed in August 2026 allege inadequate clinical-trial risk disclosures, creating investor uncertainty amid solid financial performance.
Outlook remains supported by earnings momentum and analyst buy ratings, but legal risks and high valuation multiples pose near-term headwinds. Investment opportunity hinges on legal resolution and sustained drug pipeline success, while risks include trial setbacks and regulatory scrutiny.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About General Motors Company
General Motors Co. emerged from the bankruptcy of General Motors Corp. (old GM) in July 2009. GM has eight brands and operates under four segments: GM North America, GM International, Cruise, and GM Financial. The United States now has four brands instead of eight under old GM. The company lost its U.S. market share leader crown in 2021 with share down 280 basis points to 14.6%, but we expect GM to reclaim the top spot in 2022 as 2021 suffered from the chip shortage. GM Financial became the company's captive finance arm in October 2010 via the purchase of AmeriCredit.
Read more on GM →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
